Previous Article | Next Article ![]()
Journal of Virology, April 2002, p. 3461-3470, Vol. 76, No. 7
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.7.3461-3470.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
and Oscar R. Burrone*
International Centre for Genetic Engineering and Biotechnology, 34012 Trieste, Italy
Received 10 August 2001/ Accepted 11 December 2001
|
|
|---|
|
|
|---|
NSP5, encoded in genome segment 11, is a phosphorylated and O-glycosylated serine- and threonine-rich protein (2, 12) of 198 amino acids with a molecular mass of 26 to 28 kDa. This protein shows an extraordinary level of phosphorylation that confers different electrophoretic mobilities in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), producing isoforms ranging from 28 to 32-34 kDa (2, 5, 25). We have previously reported that in vivo hyperphosphorylation of NSP5 is up-regulated by NSP2 (1). Based on indirect evidence, we and others have suggested that NSP5 has autophosphorylation activity (1, 6, 9, 25, 31).
In this report, we address the phosphorylation, kinase activity, and viroplasm localization of NSP5. Five important aspects were characterized: (i) activation of an NSP5-specific cellular kinase(s) responsible for NSP5 hyperphosphorylation, (ii) NSP5 domains involved in kinase activation, (iii) NSP5 phosphorylation sites, (iv) NSP5 phosphorylation by casein kinase II (CKII), and (v) carboxy-terminal domains responsible for NSP5 localization to viroplasms.
|
|
|---|
Immunofluorescence microscopy and antibodies. For indirect immunofluorescence microscopy, cells were fixed in 3.7% paraformaldehyde in PBS for 10 min at room temperature. Coverslips were dehydrated in PBS and blocked with 1% bovine serum albumin in PBS for 30 min and incubated with guinea pig anti-NSP2 serum (1:100) in PBS-1% bovine serum albumin for 1 h in a moist chamber at room temperature. After three washings in PBS, the slides were stained for 45 min with rhodamine isothiocyanate-conjugated goat anti-guinea pig antibody (Sigma), washed, and mounted with ProLong mounting medium (Molecular Probes). Samples were analyzed by confocal microscopy (Axiovert; Carl Zeiss). Anti-NSP5 and anti-NSP2 sera were obtained by immunization of guinea pigs with glutathione S-transferase (GST)-NSP5 or GST-NSP2 fusion proteins essentially as described previously (12).
Plasmid constructs.
The constructs pEGFP-NSP5, pEGFP-
1, pEGFP-
2, pEGFP-
3, pEGFP-
4, pEGFP-
1/
3, and pEGFP-
T were obtained by PCR from previously described constructs (1, 9) by using specific primers to incorporate EcoRI and PstI restriction sites at the N- and C-terminal ends, respectively. Similar oligonucleotides were used to construct pEGFP-
1/
4T and pEGFP-
4T. All these fragments were cloned as EcoRI/PstI fragments in pEGFP-N1 (Clontech). Internal-deletion mutants were obtained by PCR using specific internal primers for the construction of pT7v-
1/
4T, pT7v-
1/
3, and pT7v-4T and were cloned as KpnI/BamHI fragments into pcDNA3 (Invitrogen). pT7v-His6-
1/
3 and pT7v-His6-
1 were obtained by inserting the His6 tag at the N terminus with the oligonucleotides 5'-AGCTTGTACCATGGGTCATCACCATCACCATCATGGTAC-3' and 5'-CATGATGGTGATGGTGATGACCCATGGTACA-3' ligated into HindIII/KpnI sites. pT7v-His6-
1/
3 (S
A) and the other serine mutants were obtained by double-step PCR using internal oligonucleotides and were cloned as KpnI/BamHI fragments into pT7v-(His)6. pEGFP-
1/
3(S
A) was obtained by insertion of a linker sequence into pEGFP-N1 (5'-AATTCCTGGTACCACACTGCAGGTAAGG-3' and 5'-GATCCCTTA CCTGACGTGTGGTACCAGG-3') followed by cloning of a KpnI/PstI fragment from pT7v-His6-
1/
3 (S
A). GST-NSP5 was obtained by cloning a BamHI fragment of NSP5 in pGex2T (Pharmacia). Similarly, GST-
2, -
3, -
4, -
T, -
4T, -
1/
3, and -4T were obtained by cloning the respective fragments (KpnI/BamHI) into a modified pGex2T vector to include the BamHI and KpnI sites.
Oligonucleotides.
The internal primers used for the construction of the pT7v mutants were 5'-AATGGTACCATGATTGGTAGGAG-3' and 5'-GATCAGCGAGCTCTAGC-3' for pT7v-
1/
3, 5'-CGGGGTACCATGGATAATAAAAAGGAG-3' and 5'-GCGGGATCCTTACAAATCTTCGATC-3' for pT7v-4T, and 5'-AATGGTACCATGATTGGTAGGAG-3' and 5'-TTACTGCAGAGTTGAGATTGATAC-3' for pT7v-
1/
4T. The oligonucleotides used for amplification of fragments inserted in pEGFP-NSP5, pEGFP-
2, pEGFP-
3, and pEGFP-
4 were 5'-CCGGAATTCATGTCTCTCAGCATTG-3' and 5'-GATCCTTACTCGAGCAAATCTTCGATCAATTGCA-3'. The oligonucleotides for pEGFP-
1 and pEGFP-
1/
3 were 5'-CGGGAATTCATGATTGGTAGGAG-3' and 5'-GATCCTTACTCGAGCAAATCTTCGATCAATTGCA-3'. The oligonucleotides for pEGFP-
T were 5'-CCGGAATTCATGTCTCTCAGCATTG-3' and 5'-TTACTGCAGGTACTTTTTC-3'. The oligonucleotides for pEGFP-4T were 5'-CGGGAATTCATGGATAATAAAAAGGAGAAATCC-3' and 5'-GATCCTTACTCGAGCAAATCTTCGATCAATTGCA-3'. The oligonucleotides for the construction of pT7v-His6-
1/
3 (S
A) and the other serine mutants were 5'-TCAGCATCTGCATCATCTAAAACATAATCTTC-3' and 5'-GATGCTGACGCTGAAGATTATGTTTTAGATGA-3'.
Expression of GST fusion proteins.
GST fusion proteins were produced in Escherichia coli DH5
. Cultures were induced with 3 mM IPTG (isopropyl-ß-D-thiogalactopyranoside) for 3 to 4 h at 37°C. The bacteria were centrifuged, the pellet was washed with ice-cold PBS and resuspended in 1.5% laurylsarcosine-PBS, and 0.1 µg of lysozime/µl, 0.1 µg of chymostatin, leupeptin, aprotinin, and pepstatin/µl, and 5 mM dithiothreitol (DTT) were added for sonication (six times for 10 s each time). The supernatant was supplemented with 1% Triton X-100 in PBS, and equilibrated slurry beads (Glutathione Sepharose 4 Fast Flow; Amersham Pharmacia Biotech) were added. After rolling for 1 h at 4°C, the sample was centrifuged at 1,000 x g for 5 min at 4°C and washed three times with 20 volumes of PBS-1%Triton X-100. Elution was performed with 2 volumes of elution buffer (50 mM Tris-HCl [pH 8], 150 mM NaCl, 5 mM DTT, 0.1% Triton X-100, 50 mM reduced glutathione).
Purification of His6-tagged proteins. Transfected cellular extracts were incubated for 1 h at 4°C with nickel beads (nitrilotriacetic acid-agarose; Amersham Pharmacia Biotech) equilibrated in 5 volumes of loading buffer (20 mM imidazole-5 mM DTT in PBS). The beads were washed with 10 volumes of washing buffer (35 mM imidazole-5 mM DTT in PBS) and once with 35 mM imidazole, 400 mM NaCl, and 5 mM DTT in PBS. The protein was eluted with 2 volumes of elution buffer (250 mM imidazole-0.02% sodium azide-5 mM DTT in PBS) and dialyzed in PBS containing 5 mM DTT. The recovered protein was analyzed by Western blotting using guinea pig anti-NSP5 sera.
In vitro translation. The in vitro-translated proteins were synthesized essentially as described by Afrikanova et al. (2) using the TNT-T7 Coupled Reticulocyte Lysate System (Promega). Briefly, 1 µg of plasmid construct was transcribed using T7 RNA polymerase, and the transcript was translated in rabbit reticulocyte lysates in the presence of 4 µl (1,000 Ci/mmol) of [35S]methionine and incubated for 1.5 h at 30°C.
In vitro phosphorylation assays.
The in vitro phosphorylation assay was performed in a total volume of 50 µl containing 10 µl of in vitro-translated proteins, 15 µl of cellular extract, 5 µl of kinase buffer (500 mM Tris-HCl [pH 8], 15 mM spermidine, 80 mM MgCl2, 10 mM DTT, 5 mM ATP, and 50% glycerol). The reaction mixture was incubated for 25 min at 37°C, stopped with 5 µl of 50 mM EDTA, and immunoprecipitated with a guinea pig anti-NSP5 serum. For the assay with the GST fusion proteins, reactions were carried out in 50 µl of the same reaction buffer containing 0.2 µg of GST fusion protein, 1 µl of cellular extract, and 10 µCi of [
-32P]ATP (3,000 Ci/mmol) (Amersham). For the CKII assay, the substrates were incubated in a total volume of 50 µl of a reaction buffer containing 50 mM HEPES (pH 7.8), 10 mM MgCl2, 150 mM NaCl, 0.5 mM DTT, 4 µM ATP supplemented with 1 µCi of [
-32P]ATP (3,000 Ci/mmol) and 5 U of recombinant GST-CKII
/GST-CKIIß (26). Incubation was for 25 min at 30°C. ß-Casein was used as a control at 100 ng per reaction. We established the correspondence between the activities of CKII and the
1/
3 cellular extract, using the GST-
1 fusion as a substrate: 1 µl of cellular extract corresponded to approximately 0.7 U of recombinant CKII, measured under the conditions of either the in vitro phosphorylation assay or the CKII assay. Where indicated,
-phosphatase (
-Ppase) treatment was performed on immunoprecipitates in 50-µl reaction volumes containing 50 mM Tris-HCl [pH 7.8], 5 mM DTT, 6 mM MnCl2, and 2 µl of
-Ppase (400,000 U/ml; New England Biolabs) with incubation at 30°C for 2 h.
In vivo 32P labeling. The 32P labeling of 5 x 105 transfected cells was performed 15 h posttransfection. The cells were washed three times in phosphate-free minimal essential medium and then starved for 30 min in 1 ml of the same medium. Then, 30 µl of carrier-free 32Pi (10 mCi/ml; Amersham Pharmacia Biotech) was added, incubation was continued for 1 h at 37°C, and the cells were lysed as described above.
Immunoprecipitations and PAGE analysis. Kinase reaction mixtures (50 µl) and cellular extracts (50 µl) were immunoprecipitated by the addition of 1.5 µl of guinea pig anti-NSP5 serum, 1 µl of 100 mM phenylmethylsulfonyl fluoride, 50 µl of 50% protein A-Sepharose CL-4B beads (Pharmacia) in TNN buffer, and 50 µl of TNN buffer for 2 h at 4°C. The beads were washed three times with TNN buffer, and samples were analyzed by SDS-PAGE (17). Visualization of 35S-labeled proteins was enhanced by fluorography using Amplify (Amersham). Autoradiography was performed at -70°C using X-ray film (Kodak X-OMAT AR).
|
|
|---|
1 (Fig. 1 provides a description of all mutants) for the following reasons: (i) it appears as a nonhyperphosphorylated band of
20 kDa in SDS-PAGE (Fig. 2A, lane 1), (ii) it becomes hyperphosphorylated when expressed in transfected MA104 cells (1, 9) in a way that is similar to wild-type NSP5 in infected cells, and (iii) it is the most efficiently phosphorylated of all mutants tested.
![]() View larger version (56K): [in a new window] |
FIG. 1. Schematic representation of NSP5 and mutants. The dashed lines correspond to deleted regions. A, Ser Ala mutations.
|
![]() View larger version (41K): [in a new window] |
FIG. 2. In vitro phosphorylation assay. Analysis of immunoprecipitates of in vitro-translated, [35S]methionine-labeled mutant 1. (A) Substrate was incubated with cellular extracts from cells transfected with the indicated mutants; mock, extracts from cells transfected with the same plasmid without the insert. -, no addition. (B) -Ppase treatment as indicated (+, treated; -, untreated). (C) Purified His6- 1/ 3 was obtained by nickel column purification, and the same amount was used in lanes 5, 6, and 7. cell. extr., cellular extracts. The arrowheads indicate the unphosphorylated 1 substrate, and the vertical brackets indicate the positions of mobility-shifted phosphorylated forms. -, no addition.
|
1 protein, was investigated in cellular extracts derived from either untransfected cells or cells transfected with NSP5 or NSP5 deletion mutants. Extracts containing mutants
1,
3, and
1/
3, but not extracts from mock-transfected cells, had phosphorylation activity (Fig. 2A). In agreement with this result, these three mutants are hyperphosphorylated in vivo in transfected cells (9) (see Fig. 4C). Conversely, extracts from cells transfected with wild-type NSP5 showed a marginal effect, consistent with its low phosphorylation in transfected cells, in the absence of viral replication (1).
![]() View larger version (33K): [in a new window] |
FIG. 4. Characterization of Ser Ala mutants. (A) Scheme of 1/ 3 mutant showing positions of the four serines mutated to alanine within region 4. The residue numbers correspond to the wild-type protein. (B) Immunoprecipitates of in vivo 32Pi-labeled MA104 cells transfected with nonmutated (-) or with the indicated mutant constructs. The numbers refer to mutated Ser residues. (C) Western immunoblot of -Ppase-treated (+) transfected 1/ 3 mutant. (D) Phosphorylation with [ -32P]ATP of GST- 1/ 3 and GST- 1/ 3(S A) as for Fig. 3.
|
-Ppase confirmed that PAGE mobility changes corresponded to hyperphosphorylated forms of the substrate (Fig. 2B). Interestingly, extracts transfected with the two mutants that lack region 3 (
3 and
1/
3) showed the highest phosphorylation activities. Extracts from cells transfected with other mutants, such as
2,
4,
T, or
1/
3/
T, did not show significant activity. Table 1 shows the activities of all mutants tested. In all cases, similar amounts of transfected proteins were used, as judged by Western blot analysis. From these results, it appears that domains 2, 4, and T are absolutely required for extract activities. Also, other mutants were tested as substrates in this assay (Table 1). |
View this table: [in a new window] |
TABLE 1. Summary of NSP5 properties
|
1 were only achieved with extracts from cells transfected with NSP5 mutants that showed hyperphosphorylation in vivo. This result suggested that either the activity resides in the transfected protein itself or the transfected protein induces or activates an otherwise-inactive cellular kinase(s).
To discriminate between these two hypotheses, a His6-tagged version of the
1/
3 protein was purified from transfected cellular extracts on a nickel column. The purified protein was analyzed by Western immunoblotting (not shown). As shown in Fig. 2C, the cellular extract containing His6-
1/
3 showed phosphorylation activity (lane 5) while the same amount of the purified protein did not (lane 7).
The possibility that the transfected NSP5 mutant is complexed with a cellular kinase, thus activating phosphorylation of NSP5 itself, seems unlikely, since addition of purified His6-
1/
3 to a mock cellular extract did not reconstitute the activity (Fig. 2C, lane 6). This suggests that expression of the protein is necessary to promote activation of the cellular kinase(s). Hyperphosphorylation of NSP5 in virus-infected cells also occurs in the presence of actinomycin D, indicating that transcription of cellular genes is not required for the emergence of the kinase activity (data not shown). Phosphorylation and the capacity to activate the cellular kinase(s) appear to be distinct characteristics of NSP5. Indeed, mutation of four serine residues within domain 4 [mutant
1/
3(S
A)], which completely abolished phosphorylation of the protein expressed in vivo (see below), did not affect its ability to activate the cellular kinase(s) (Fig. 2C).
Mapping phosphorylation sites of NSP5.
In order to map the phosphorylation sites on NSP5, we constructed a variety of NSP5 deletion mutants as GST fusion proteins. None of these proteins produced in bacteria showed any phosphorylation activity (Fig. 3) nor were they phosphorylated by His6-
1/
3 purified from transfected cells (data not shown). This evidence supports the idea that NSP5 does not have kinase activity. However, some of the mutants, as well as wild-type NSP5, served as substrates when incubated in vitro with a cellular extract from
1/
3-transfected cells as a source of enzyme. As shown in Fig. 3, only mutants containing region 4 were phosphorylated, indicating that most of the phosphorylation occurs within this domain and suggesting that in vivo phosphorylation sites could reside in this region. We have previously reported that NSP5 phosphorylation takes place in Ser and Thr residues (2). To further characterize the phosphorylation sites, we mutated to alanine (in mutant
1/
3) four serines (Ser153, Ser155, Ser163, and Ser165) within region 4 present (boldface) in a particular acidic amino acid context (ADSDSEDYVLDDSDSDDG) (Fig. 4A) and tested them for the ability to be phosphorylated in vivo. Figure 4B shows immunoprecipitates of several transfected
1/
3 Ser
Ala mutants following labeling with 32Pi. The four serines appeared to be sites of phosphorylation. The only mutant that showed no phosphorylation was the one with all four serines mutated (Fig. 4B, lane 9). All of the lanes in Fig. 4B contained comparable amounts of transfected protein as determined by Western immunoblotting (not shown). The double band corresponded to low-mobility hyperphosphorylated forms, as judged by
-Ppase sensitivity (Fig. 4C). Further confirmation that the four serines within region 4 are the main phosphorylation sites was obtained with a GST-
1/
3 fusion protein with all four serines mutated [GST-
1/
3(S
A)] which was not phosphorylated by
1/
3 cellular extracts (Fig. 4D).
![]() View larger version (25K): [in a new window] |
FIG. 3. Mapping phosphorylation sites of NSP5. SDS-PAGE analysis of immunoprecipitated, in vitro-phosphorylated GST-NSP5 mutant proteins (0.2 µg) incubated with (+) and without (-) cellular extract (cel. extr.) from 1/ 3-transfected cells. GST protein negative control (-) (lane 17) was loaded without immunoprecipitation.
|
1/
T,
1/
3, and
2. This phosphorylation appeared to be restricted to serines 153, 155, 163, and 165, since the mutant GST-
1/
3(S
A) was not phosphorylated by CKII. This result is in complete agreement with the lack of phosphorylation of this mutant in vivo (Fig. 4B). CKII was also able to phosphorylate the in vitro-translated His6-
1 substrate, as demonstrated by the results shown in Fig. 5B. The left panel shows both the 35S label of the in vitro-translated substrate and the 32P label from [
-32P]ATP. In the right panel, only the 32P radioactivity was detected. Under these conditions, CKII was able to convert part of the substrate into mobility-shifted forms, similarly to the transfected cellular extracts. Phosphorylation of the GST fusions with CKII was also performed under the conditions used with the cellular extracts with similar results. These results suggested that a CKII-like enzymatic activity is involved in NSP5 phosphorylation.
![]() View larger version (44K): [in a new window] |
FIG. 5. NSP5 is a substrate of CKII. Shown is SDS-PAGE analysis of an in vitro CKII phosphorylation assay with [ -32P]ATP. (A) The indicated GST-NSP5 mutants were used as substrates. Positive and negative controls are shown in lanes 1, 7, 8, and 9. -, no substrate added. (B) Purified, in vitro-translated 35S-His6- 1 was used as a substrate in the presence or absence of CKII. The two panels show autoradiography of the same gel, detecting 35S plus 32P (left) and 32P (right). The solid and open arrowheads indicate His6- 1 precursor and hyperphosphorylated forms, respectively. Autophosphorylated GST- and GST-ß CKII subunits are indicated. +, present; -, absent.
|
Figure 6 shows that, in noninfected cells, NSP5 wild type and mutants have a diffused distribution in the cytoplasm. Following infection, this distribution was highly affected, both for NSP5 and for some of the deletion mutants, such as
1,
2,
3, and
1/
3, which became rapidly relocalized in viroplasms. On the other hand, mutants lacking region 4 (such as
4) or the carboxy-terminal tail (
T) (not shown) did not localize to viroplasms. Table 1 summarizes the results obtained with all mutants tested. Interestingly, mutant
1/
3(S
A) with all four serines in region 4 mutated, which we previously demonstrated not to be phosphorylated in vivo (see above), showed a clear colocalization in viroplasms. This result suggested that, although the presence of the carboxy-terminal regions 4 and T is required, phosphorylation is not essential for NSP5 localization to viroplasms in the context of infected cells.
![]() View larger version (57K): [in a new window] |
FIG. 6. Confocal immunofluorescence microscopy. MA104 cells were transfected with NSP5 mutants fused to EGFP followed by infection with rotavirus. Viroplasms were detected with an anti-NSP2 (red) antibody. The rightmost column is the superimposition of the two independently acquired images.
|
2, which does not get phosphorylated in vivo and does not form VLS (9) whereas it localized to viroplasms (Fig. 6). This is most likely due to interaction with wild-type NSP5, which was shown to depend on the last 10 carboxy-terminal amino acids (31). We have now determined that localization to VLS was only obtained when
2-EGFP was cotransfected with NSP2 into a cell line stably expressing NSP5 (MA104-C7) (2) and not when it was cotransfected into a cell not expressing NSP5 (data not shown). |
|
|---|
1,
3, or
1/
3, respectively) efficiently induce PAGE mobility shift in an in vitro-translated NSP5-derived substrate. Consistent with these results, these same mutants were previously shown to undergo mobility shift phosphorylation in vivo (9). Similarly, cell extracts of mutants lacking region 2, 4, or T, which were inactive in the assay, were unable to be phosphorylated in vivo (9) in spite of the fact that two of them (
2 and
T) contain region 4. Interestingly, a cellular extract of cells transfected with the histidine-tagged version of mutant
1/
3 (His6-
1/
3) showed high activity while the purified protein did not. Moreover, GST fusion proteins showed a complete lack of kinase activity, whereas they were good substrates. Taken together, these results indicate that NSP5 is not itself a kinase but rather that it activates a cellular kinase(s), otherwise inactive in the untransfected cellular extracts, for its own phosphorylation.
The marginal phosphorylation activity of extracts containing wild-type NSP5 is not surprising, since when expressed alone, NSP5 is very little phosphorylated, producing mainly the 26-kDa polypeptide (1, 9), while upon coexpression with NSP2 it becomes hyperphosphorylated (1). Regions 1 and 3 appear to have an inhibitory effect (region 3 being stronger than region 1 [Fig. 2A]) on the capacity of NSP5 to activate the cell kinase(s), as revealed by the activities of mutants
1,
3, and
1/
3. One could speculate that in the replicative cycle, interaction with NSP2 may neutralize the inhibition of these two regions.
Region 4 contains the main phosphoacceptor sites, mapped to serines 153, 155, 163, and 165, located in an acidic region with homology to CKII phosphorylation sites (SDSE and SDSD) (19). In fact, we showed that CKII was able to phosphorylate NSP5 in vitro precisely in those positions, although this does not demonstrate that CKII is the kinase responsible for NSP5 phosphorylation in vivo or that other kinases may not be involved. These results suggest that the cellular kinase(s) activated by NSP5 is a CKII-like enzyme. Up to now, CKII has been described as phosphorylating several viral proteins of both DNA and RNA viruses (7, 13, 15, 16, 20, 22, 23), with the exception of viruses of the family Reoviridae.
It is noteworthy that phosphorylation of the four serines in region 4 appears not to be required for kinase activation, since mutant
1/
3(Ser
Ala) was still able to induce the cellular kinase(s).
Many questions concerning the phosphorylation of NSP5 and its ability to localize in viroplasms await the development of a reverse genetic system. We have previously demonstrated that NSP5 and NSP2 can form VLS independently of the viral context. The formation of these particular cytoplasmic structures reflects the abilities of the two nonstructural proteins to interact with each other. On the other hand, in the context of viral infection, the situation is more complex and localization can also involve the interaction of mutants with wild-type NSP5 (31). Contrary to what was observed with VLS formation, all NSP5 mutants containing regions 4 and T localized to viroplasms independently of the phosphorylation state. Interaction with wild-type NSP5 could explain this behavior, since multimerization of NSP5 was shown to depend on the last 10 carboxy-terminal amino acids (31). In fact, mutant
2 is not phosphorylated in vivo and does not form VLS (9), whereas in this report we show localization to viroplasms. This attribute was dependent on complementation with wild-type NSP5, since VLS were formed only when
2-EGFP was cotransfected with NSP2 into a cell line stably expressing NSP5.
Even though the biological function of NSP5 remains to be elucidated, the data presented here delineate meaningful aspects of NSP5 phosphorylation in the context of virus replication.
C.E., F.V., and E.F. were supported by SISSA predoctoral fellowships.
We are grateful to Francisco Romero-Oliva for providing the recombinant CKII and to Mauro Sturnega and Giancarlo Lunazzi for excellent technical assistance.
Present address: Centre for Rare Diseases, IRCCS, Ospedale Burlo Garofolo, 34137 Trieste, Italy. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»